Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 87

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Non-small cell lung cancer

Not recruiting

Study of Sotorasib Alone and Combined with Pembrolizumab in Adult Patients with Advanced Solid Tumors Having KRAS p.

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sotorasib
  • Sponsor:Amgen Inc.

Idiopathic pulmonary fibrosis

Not recruiting

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Non-small cell lung cancer

Not recruiting

Study of Farletuzumab Ecteribulin for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Farletuzumab Ecteribulin
  • Sponsor:Bristol Myers Squibb International Corporation

Alpha-1 antitrypsin deficiency+1

Not recruiting

Study Comparing INBRX-101 and Human Alpha1-Proteinase Inhibitor for Adults with Alpha-1 Antitrypsin Deficiency Emphysema

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Human ALPHA-1-PROTEINASE inhibitor immunoglobulin G fusion protein, recombinant
  • Sponsor:Sanofi AATD Inc.

Influenza

Not recruiting

Study of intravenous zanamivir safety and effectiveness in infants under 6 months of age with complicated influenza infection

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Zanamivir
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer

Not recruiting

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

K-ras gene mutation+1

Not recruiting

Study of Sotorasib Treatment in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation Who Have Previously Received Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sotorasib
  • Sponsor:Institut Gustave Roussy

Pulmonary hypertension

Not recruiting

Study on Treprostinil Palmitil Inhalation Powder for Patients with Pulmonary Hypertension and Interstitial Lung Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Non-small cell lung cancer stage IV

Not recruiting

Study of Pembrolizumab, Olaparib, and Pemetrexed for Patients with Stage IV Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Chronic obstructive pulmonary disease

Not recruiting

Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Asthmatic crisis

Not recruiting

Study on the Effects of Verekitug (UPB-101) for Adults with Severe Asthma

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 kappa monoclonal antibody against CRLF2
  • Sponsor:Upstream Bio Inc.

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.